These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 37854581)

  • 1. The Benefits of Polypill: Adherence and Chronotherapy [Response to Letter].
    Lopez-Jaramillo P; Lopez-Lopez JP
    Vasc Health Risk Manag; 2023; 19():661-662. PubMed ID: 37854581
    [No Abstract]   [Full Text] [Related]  

  • 2. Polypill Brings Benefits to Patients with Cardiovascular Disease, Both Improving Medication Adherence and Demonstrating the Concept of Chronotherapy [Letter].
    Zhu LL; Zhou Q
    Vasc Health Risk Manag; 2023; 19():659-660. PubMed ID: 37790123
    [No Abstract]   [Full Text] [Related]  

  • 3. The polypill: from concept and evidence to implementation.
    Yusuf S; Pinto FJ
    Lancet; 2022 Nov; 400(10364):1661-1663. PubMed ID: 36243022
    [No Abstract]   [Full Text] [Related]  

  • 4. Polypill Better for Secondary Cardiovascular Prevention Than Physician-Directed Care.
    Ebell MH
    Am Fam Physician; 2023 Mar; 107(3):318-319. PubMed ID: 36920802
    [No Abstract]   [Full Text] [Related]  

  • 5. Could the polypill improve adherence? The patient perspective.
    Bryant L; Martini N; Chan J; Chang L; Marmoush A; Robinson B; Yu K; Wong M
    J Prim Health Care; 2013 Mar; 5(1):28-35. PubMed ID: 23457692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The Polypill - A Practicable Approach?].
    Thürmann PA; Kleinerüschkamp AG; Boehme P
    Dtsch Med Wochenschr; 2019 Jun; 144(11):715-718. PubMed ID: 31163467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Polypill for cardiovascular disease prevention: the SECURE study].
    Di Fusco SA; Colivicchi F
    G Ital Cardiol (Rome); 2023 May; 24(5):333-335. PubMed ID: 37102344
    [No Abstract]   [Full Text] [Related]  

  • 8. Strengths and Limitations of Using the Polypill in Cardiovascular Prevention.
    Roy A; Naik N; Srinath Reddy K
    Curr Cardiol Rep; 2017 May; 19(5):45. PubMed ID: 28425033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A SECURE polypill as a strategy at the heart of secondary prevention.
    Liuzzo G; Patrono C
    Eur Heart J; 2022 Nov; 43(43):4534-4535. PubMed ID: 36148477
    [No Abstract]   [Full Text] [Related]  

  • 10. The Polypill at 20 - What Have We Learned?
    Wang TJ
    N Engl J Med; 2022 Sep; 387(11):1034-1036. PubMed ID: 36018010
    [No Abstract]   [Full Text] [Related]  

  • 11. Treating many conditions--with just one pill. The polypill could make your medicines much easier to take.
    Harv Womens Health Watch; 2012 Dec; 20(4):5. PubMed ID: 23346615
    [No Abstract]   [Full Text] [Related]  

  • 12. Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?
    Franczyk B; Gluba-Brzózka A; Jurkiewicz Ł; Penson P; Banach M; Rysz J
    Expert Opin Pharmacother; 2018 Dec; 19(17):1857-1865. PubMed ID: 30295098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Step Ahead in Secondary Prevention of Cardiovascular Risk. Consensus Document on Clinical Use of the Polypill.
    González-Juanatey JR; Mostaza JM; Lobos JM; Abarca B; Llisterri JL
    Rev Esp Cardiol (Engl Ed); 2016 Jun; 69(6):547-50. PubMed ID: 27062678
    [No Abstract]   [Full Text] [Related]  

  • 14. The polypill and medicines access: two decades and counting.
    Rodgers A; Smith R
    BMJ; 2023 Aug; 382():1847. PubMed ID: 37562792
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
    Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A;
    Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One Pill for Everyone? Twenty Years of Polypill for Cardiovascular Disease.
    Tran RJC
    Am J Cardiol; 2023 Sep; 203():493-495. PubMed ID: 37500317
    [No Abstract]   [Full Text] [Related]  

  • 17. Polypill treatments for cardiovascular diseases.
    Webster R; Rodgers A
    Expert Opin Drug Deliv; 2016; 13(1):1-6. PubMed ID: 26558898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular disease and statin drugs.
    Campbell AW
    Altern Ther Health Med; 2014; 20(5):8-9. PubMed ID: 25141364
    [No Abstract]   [Full Text] [Related]  

  • 19. Helping our patients to adhere to chronic medications: a new arrow for the quiver.
    Shrank WH
    J Gen Intern Med; 2011 Dec; 26(12):1394-5. PubMed ID: 21979760
    [No Abstract]   [Full Text] [Related]  

  • 20. Adherence to cardiovascular pharmacotherapy by patients in Iraq: A mixed methods assessment using quantitative dried blood spot analysis and the 8-item Morisky Medication Adherence Scale.
    Alalaqi A; Lawson G; Obaid Y; Tanna S
    PLoS One; 2021; 16(5):e0251115. PubMed ID: 33989336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.